NEWS DETAIL

Nuevo referente para las terapias dirigidas en el cáncer de pulmón: la mediana de supervivencia libre de progresión para lorlatinib en el cáncer de pulmón de células no pequeñas ALK+ avanzado supera los 5 años – Publicaciones de ASCO

New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non–Small Cell Lung Cancer Surpasses 5 years ASCO Publications

Información médica

该文章暂未提取到完整正文,已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。

Produk Berkaitan Artikel Ini

Produk ini dipadankan secara automatik berdasarkan tajuk, ringkasan, dan kandungan artikel.

Soalan Lazim

Which products are related to this article?

The system matched these relevant products from the article content: LORLADX Lorlatinib Lucius Lorlatinib – Beli Dalam Talian LORLADX Lorlatinib 100mg.

How can I view the medicines discussed in this article?

Use the related product cards below the article to review available specifications, prices, product information, and reviews.

Does this article replace advice from a doctor or pharmacist?

No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.

WhatsApp WhatsApp WeChat WeChat